Exploration of databases and methods supporting drug repurposing: a comprehensive survey
Open accessThe DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
Abstract
Drug development involves a deep understanding of the mechanisms of action and possible side effects of each drug, and sometimes results in the identification of new and unexpected uses for drugs, termed as drug repurposing. Both in case of serendipitous observations and systematic mechanistic explorations, confirmation of new indications for a drug requires hypothesis building around relevant drug-related data, such as molecular targets involved, and patient and cellular responses. These datasets are available in public repositories, but apart from sifting through the sheer amount of data imposing computational bottleneck, a major challenge is the difficulty in selecting which databases to use from an increasingly large number of available databases. The database selection is made harder by the lack of an overview of the types of data offered in each database. In order to alleviate these problems and to guide the end user through the drug repurposing efforts, we provide here a survey of 102 of the most promising and drug-relevant databases reported to date. We summarize the target coverage and types of data available in each database and provide several examples of how multi-database exploration can facilitate drug repurposing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
KEGG: Kyoto Encyclopedia of Genes and Genomes
Kanehisa, M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.27 · Cited by 37,077 · cited 5×
“Among pathway databases, KEGG [85] is one of the most comprehensive and nonredundant database (0.”
MethodInfluentialKEGG: Kyoto Encyclopedia of Genes and Genomes
Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H., & Kanehisa, M. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.29 · Cited by 31,232
An integrated encyclopedia of DNA elements in the human genome
The ENCODE Project Consortium (2012) · Nature · doi:10.1038/nature11247 · Cited by 18,072
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160 · cited 1×
“[10, 23]), including: DepMap [26], cBioPortal [27], Probes & Drugs portal [28], DrugComb [29], DrugTargetCommons(DTC) [30], DrugTargetProfiler (DTP) [31], IDAAPM [32], PharmacoDB [33] and DisGeNet [34].”
MethodRobust enumeration of cell subsets from tissue expression profiles
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 13,224
STRING v10: protein–protein interaction networks, integrated over the tree of life
Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., Simonovic, M., Roth, A., Santos, A., Tsafou, K. P., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1003 · Cited by 10,436 · cited 2×
“Addition of PPI data from STRING [72] D ow nloaded from https://academ ic.oup.com /bib/advance-article-abstract/doi/10.1093/bib/bbaa003/5735620 by guest on 11 M arch 2020 generated a new method, termed HNMDRP, that outperformed several state-of-the-art machine learning-based methods in correctly correlating responses…”
MethodInfluentialNCBI GEO: archive for functional genomics data sets—update
Barrett, T., Wilhite, S. E., Ledoux, P., Evangelista, C., Kim, I. F., Tomashevsky, M., Marshall, K. A., Phillippy, K. H., Sherman, P. M., Holko, M., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1193 · Cited by 10,418
The Human Genome Browser at UCSC
Kent, W. J., Sugnet, C. W., Furey, T. S., Roskin, K. M., Pringle, T. H., Zahler, A. M., & Haussler, A. D. (2002) · Genome Research · doi:10.1101/gr.229102 · Cited by 10,400
KEGG: new perspectives on genomes, pathways, diseases and drugs
Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y., & Morishima, K. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1092 · Cited by 8,865 · cited 4×
“Hence, we assigned ‘Pathways’ as primary subcategory for KEGG, which is listed under the main category ‘biomolecular’, as shown in Table 2.”
BackgroundInfluential
Research works printed but not linked: 1
- Lotfi Shahreza, 2018, A review of network-based approaches to drug repositioning, Brief Bioinform, 19, 878, 10.1093/bib/bbx017 · DOI · Paper page
Cited by
Items 101–133 of 133
Marxer, C., Rölke, H., Alfieri, A., & Halatsch, M. (2023) · IEEE Swiss Conference on Data Science (SDS) · doi:10.1109/sds57534.2023.00009 · Cited by 1
“After designating the biomedical entity types of A&B as starting pairs, we determined the most suitable database on the recommendations based on previous research by Tanoli et al. [8].”
InfluentialDrug Repurposing: Strategies and Study Design for Bringing Back Old Drugs to the Mainline
Schcolnik‐Cabrera, A. (2023) · Springer eBooks · doi:10.1007/978-981-99-1284-1_36 · Cited by 1
Essential database resources for modern drug discovery
Yadav, S., Koka, S. S., Jain, P., Darwhekar, G. N., & Vinchurkar, K. (2025) · Advances in pharmacology · doi:10.1016/bs.apha.2025.01.002 · Cited by 2
Zhang, P., Ke, Z., Mao, X., Zhang, X., & Xiao, W. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c02298 · Cited by 1
Tsuchiya, M., Inoue, M., Kawazoe, Y., Shimamoto, K., Seki, T., Imai, S., Kizaki, H., Shinohara, E., Yada, S., Wakamiya, S., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.116157 · Cited by 2
Organoids for Drug Repurposing: A Literature Review
Okuyama, R. (2025) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1155/jcpt/8827167 · Cited by 1
“More than 100 databases are currently available to support such eforts [3].”
Mou, Z., Tian, Z., Jin, J., Yu, H., & Huang, Y. (2026) · Biomolecules · doi:10.3390/biom16060830 · Cited by 1
“Adverse event (AE)–based methods treat spontaneous clinical observations as real-world phenotypic signals for identifying new therapeutic uses of existing drugs [74].”
Old drugs and new opportunities—Drug repurposing in colon cancer prevention
Sarojamma, V., Gupta, M. K., Shaik, J. B., & Vadde, R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-15280-1.00010-8 · Cited by 1
Bigdata of National Medicine Registers
Савосина, П. И., Druzhilovskiy, D. S., Filimonov, D. A., & Poroikov, V. (2024) · Biomedical Chemistry Research and Methods · doi:10.18097/bmcrm00230 · Cited by 2
Using BERT to identify drug-target interactions from whole PubMedPreprint
Aldahdooh, J., Vähä-Koskela, M. J. V., Tang, J. P., & Tanoli, Z. (2021) · Research Square · doi:10.21203/rs.3.rs-1015236/v1 · Cited by 1
Self-citationWang, Y., Aldahdooh, J., Hu, Y., Yang, H., Vähä-Koskela, M. J. V., Tang, J. P., & Tanoli, Z. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.21.488995 · Cited by 1
“On the other hand, there are hundreds of databases that can indirectly support drug repurposing [7][11].”
BackgroundSelf-citationDóra, D., Dóra, T. B., Szegvári, G., Gerdán, C., & Lohinai, Z. (2022) · Research Square · doi:10.21203/rs.3.rs-1257157/v1
BGAT: A Multi Information Fusion Drug Repurposing Framework Based on Graph Convolutional Network
Sun, D., Wang, Z., Jiang, S., & Huang, W. (2022) · International Conference on Innovation in Artificial Intelligence (ICIAI) · doi:10.1145/3529466.3529498
“At the same time, a series of effective research methods related to artificial intelligence, such as machine learning and deep learning, are gradually applied to various fields and many relevant public databases are continuously maintained and updated[3], computational drug repurposing has attracted more and more atte…”
BackgroundTools and Data Towards Supporting Quantitative Systems Pharmacology of the Eye – An OverviewPreprint
Kuepfer, L., Fuellen, G., & Stahnke, T. (2022) · Preprints.org · doi:10.20944/preprints202203.0164.v2
Strategies for drug repurposing
Vema, A., & Kalle, A. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-15280-1.00017-0
Sisakht, M., Shahrestanaki, M. K., Fallahi, J., & Razban, V. (2024) · Current Computer - Aided Drug Design · doi:10.2174/0115734099274495231218150611
Additional file 1 of Using BERT to identify drug-target interactions from whole PubMed
Aldahdooh, J., Vähä-Koskela, M. J. V., Tang, J. P., & Tanoli, Z. (2022) · Figshare · doi:10.6084/m9.figshare.20115831
Self-citationFinding Second-Generation Pharmacochaperones: Getting Help From Computational Methods
Verdino, A., Scafuri, B., Parrone, D., D’Arminio, N., Pascarella, S., Via, A., & Marabotti, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95502-7.00202-5
Drug Repurposing and Multi-Target Therapies
Şahin, Ş., Önel, Ö., Kızılay, E. B., & Serçinoğlu, O. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95502-7.00238-4
Krosuri, P., & Mothilal, M. (2025) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2025v17i2.52603
“Gene sets associated with AP were extracted from each database to compile a comprehensive pool of candidate genes for subsequent analysis [26, 27].”
Krosuri, P., & Mohan, M. (2025) · Current Drug Discovery Technologies · doi:10.2174/0115701638359244250411045740
Modern Computational Intelligence Based Drug Repurposing for Cancer
Budha, R. R., Khan, N., Khan, S., Attar, E. S., & Rao, G. K. (2025) · Springer eBooks · doi:10.1007/978-981-96-4154-3_23
Bioinformatics tools for drug repurposing: a tutorial using heart failure as a case study
Fonseca, I., Trindade, F., Santos, M. J. D. S., Leite-Moreira, A. F., Moreira‐Gonçalves, D., Vitorino, R. M. P., Ferreira, R. M., & Nogueira‐Ferreira, R. (2025) · Journal of Molecular and Cellular Cardiology Plus · doi:10.1016/j.jmccpl.2025.100460
Aslam, M., Iftikhar, S., Amber, M., Amin, J., Yousaf, K., Ain, Q. U., & Naz, E. (2024) · Journal of Microbiological Sciences · doi:10.38211/jms.2024.03.157
“…pathways to analyze repurposed drugs and the identification of potential off-target effects of present medications, leading to the discovery of new therapeutic applications are all driven by Bioinformatics reducing the financial barriers (Tanoli, et al ., 2021; Amiri Ssouri et al ., 2023).”
Marchesin, S., & Silvello, G. (2022) · Figshare · doi:10.6084/m9.figshare.19494868
Marchesin, S., & Silvello, G. (2022) · Figshare · doi:10.6084/m9.figshare.19494871
Korra, B. T., Roffin, K., Singh, S., Kar, S. S., Kundal, K., Sengupta, A., & Kumar, R. (2025) · Springer handbooks · doi:10.1007/978-3-031-81728-1_41 · Cited by 1
Survey on Deep Learning Methods in Drug Repurposing
Elsoud, A. A., Mounir, M., Gad, W. K., & Badr, N. L. (2025) · International Conference on Intelligent Computing and Information Systems (ICICIS) · doi:10.1109/icicis66182.2025.11313173 · Cited by 1
From Code to Cure: Computational Strategies in Drug Repurposing
Sijina, K. P., & Rajanikant, G. K. (2025) · Springer handbooks · doi:10.1007/978-3-031-81728-1_32 · Cited by 1
Feng, M., Jia, G., Li, Q., Li, J., Wang, C., Han, W., Shi, J., Yan, C. H., Han, Y., & Zhou, Z. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124259
Unique therapeutic potential of bacterial metabolites for cancer chemotherapy
DEBNATH, A., Imamura, D., Kawase, T., MAITY, A., & Koley, H. (2026) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2026.06.001
Prapa, P. M., Saba, A. A., Hosen, M. R., Bhattacharjee, P., Majumder, B. K., Palit, P., Guinto, M. C., & Sarker, P. K. (2026) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2026.100529
Multiomics integration and causal inference in aging research—can the molecular gap be bridged?
Wei, L., & Ni, X. (2026) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2026.56
Metadata
- Authors
- Tanoli, Z., Seemab, U., Scherer, A., Wennerberg, K., Tang, J., & Vähä-Koskela, M.
- Affiliations
- University of Helsinki (FI)
- University of Copenhagen (DK)
- Corresponding author
- Tanoli, Ziaurrehman
- Tang, Jing
- Vähä-Koskela, Markus
- ORCID
- Venue
- Briefings in Bioinformatics
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-02-14
- Volume
- 22
- Issue
- 2
- Pages
- 1656-1678
- ISSN
- 1467-5463 (ISSN-L)
- 1477-4054
- PMC
- PMC7986597
- OpenAlex
- W3006508031
- Semantic Scholar
- 31b64604c660c457f13b7adb6a3ac7baf643b9f7
- Cited by
- 131
- References
- 167
- Citations by year
- 2026: 9 · 2025: 23 · 2024: 22 · 2023: 25 · 2022: 25 · 2021: 17 · 2020: 10
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Briefings in Bioinformatics (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- Työväentutkimus Vuosikirja (submittedVersion)
- Funders
- European Research Council (716063)
- Academy of Finland (317680)
- European Commission (824087)
- Medicinska Understödsföreningen Liv och Hälsa
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Health Informatics › Biomedical Text Mining and Ontologies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Keywords
- drug repurposing, drug databases, database selection, molecular targets, drug mechanisms of action, adverse drug reactions, drug discovery
- MeSH terms
- Surveys and Questionnaires, Databases, Factual, Drug Delivery Systems, Computational Biology, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.